Benjamin Pariente

Benjamin Pariente

Auto-generated profile, based on publicly available information

Benjamin Pariente

Hepato-Gastroenterology Department, Claude Huriez Hospital, University of Lille, Lille, France

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2015 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
Laurent Peyrin-birouletLaurent Peyrin-biroulet
Laurent Peyrin-biroulet
WSW Sandborn
W Sandborn
BSB E Sands
B E Sands
WRW Reinisch
W Reinisch
WBW Bemelman
W Bemelman
JCJ -F Colombel
J -F Colombel
OBJECTIVES:The Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program was initiated by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). It examined potential treatment targets for inflammatory bowel disease (IBD) to be used for a “treat-to-ta

1 June 2011 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
BPBenjamin Pariente
Benjamin Pariente
JCJacques Cosnes
Jacques Cosnes
SDSilvio Danese
Silvio Danese
WSWilliam J Sandborn
William J Sandborn
MLMaïté Lewin
Maïté Lewin
MLMarc Lémann
Marc Lémann
Crohn's disease (CD) is a chronic progressive destructive disease. Currently available instruments measure disease activity at a specific point in time. An inst

1 January 2015 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
BPBenjamin Pariente
Benjamin Pariente
JMJean-Yves Mary
Jean-Yves Mary
SDSilvio Danese
Silvio Danese
YCYehuda Chowers
Yehuda Chowers
PCPeter De Cruz
Peter De Cruz
JCJacques Cosnes
Jacques Cosnes

1 April 2018 in Gastroenterology
Verified
Journal Article
Closed access
GDGeert R. D’Haens
Geert R. D’Haens
SVSeverine Vermeire
Severine Vermeire
GLGuy Lambrecht
Guy Lambrecht
FBFilip Baert
Filip Baert
PBPeter Bossuyt
Peter Bossuyt
SWSabrina Williams
Sabrina Williams

1 August 2017 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PDF file
Anthony BuissonAnthony Buisson
Anthony Buisson
FGFlorent Gonzalez
Florent Gonzalez
FPFlorian Poullenot
Florian Poullenot
SNStephane NANCEY
Stephane NANCEY
ESElisa Sollellis
Elisa Sollellis
GBGuillaume Bouguen
Guillaume Bouguen
Objective control of intestinal inflammation during inflammatory bowel disease (IBD) is becoming the main driver for medical treatment. However, the monitoring tools-related burden remains poorly investigated. We aimed to evaluate their comparative acceptability and utility according to patients with IBD. After a preliminary phase, the final questionnaire encompassing self-administered and physician questionnaires was prospectively and consecutively submitted to 916 patients with IBD from 20 public and private centers. Acceptability and utility visual analog scales (VAS) were expressed as median with interquartile range. Regarding the group of patients with Crohn's disease (n = 618), venipuncture (VAS = 9.3 [8.8–9.7]) and ultrasonography (VAS = 9.3 [8.7–9.7]) were the most acceptable tools (P < 0.0001, for each comparison), whereas rectosigmoidoscopy was the least acceptable tool (VAS = 4.4 [1.2–7.3]) (P < 0.0001, for each comparison). Wireless capsule endoscopy (VAS = 8.5 [5.2–9.3]), magnetic resonance enterocolonography (VAS = 8.0 [5.0–9.2]), and stools collection (VAS = 7.7 [4.6–9.3]) were more acceptable than colonoscopy (VAS = 6.7 [4.3–8.9]) (P < 0.0001, for each comparison). The acceptability was assessed in 298 patients with ulcerative colitis for venipuncture (VAS = 9.4 [8.8–9.7]), stools collection (VAS = 8.1 [5.7–9.4]), colonoscopy (VAS = 7.5 [4.7–9.2]), and rectosigmoidoscopy (VAS = 6.7 [2.8–9.1]); (P < 0.001 for each comparison). All monitoring tools were considered as highly useful by patients with IBD. Decreased acceptability was related to embarrassment for the collection/transport of stools (60.7%), bowel cleansing (76.3%) for colonoscopy, abdominal discomfort (51.3%) and rectal enema (36.6%) for rectosigmoidoscopy, bowel distension (48.3%) for magnetic resonance enterocolonography, and potential capsule retention (21.4%) for wireless capsule endoscopy. Among the IBD monitoring tools, endoscopy demonstrated the lowest acceptability supporting the development of alternative modalities. Patients' information and examination conditions should be improved to ensure proper monitoring adherence.

1 November 2016 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
AAAMIOT Aurelien
AMIOT Aurelien
JGJean-Charles Grimaud
Jean-Charles Grimaud
Laurent Peyrin-birouletLaurent Peyrin-biroulet
Laurent Peyrin-biroulet
JFJerome Filippi
Jerome Filippi
BPBenjamin Pariente
Benjamin Pariente
JQJawad Al Qaddi
Jawad Al Qaddi